211 related articles for article (PubMed ID: 23253000)
1. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
2. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Montani D; Humbert M
Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
[No Abstract] [Full Text] [Related]
3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
4. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
Stähler G
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092
[TBL] [Abstract][Full Text] [Related]
5. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Humbert M
Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
[No Abstract] [Full Text] [Related]
6. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Faruqi S; Fathi H; Morice AH
Int J Cardiol; 2010 Oct; 144(3):e43-5. PubMed ID: 19171388
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based approach to the management of pulmonary arterial hypertension.
Coyne TC
Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019
[No Abstract] [Full Text] [Related]
8. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Rondelet B; Dewachter L; Kerbaul F; Dewachter C; Hubloue I; Fesler P; Franck S; Remmelink M; Brimioulle S; Naeije R
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396
[TBL] [Abstract][Full Text] [Related]
9. Endothelin antagonism in pulmonary arterial hypertension.
Lee SH; Channick RN
Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
[TBL] [Abstract][Full Text] [Related]
10. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.
Lee WT; Kirkham N; Johnson MK; Lordan JL; Fisher AJ; Peacock AJ
Eur Respir J; 2011 Feb; 37(2):472-4. PubMed ID: 21282815
[No Abstract] [Full Text] [Related]
11. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
12. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
Catapano-Minotti G; Corsonello A; Guadalupi G; Spani R; Antonelli-Incalzi R
Intern Med; 2008; 47(6):511-3. PubMed ID: 18344637
[TBL] [Abstract][Full Text] [Related]
13. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
Hoeper MM
Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
[No Abstract] [Full Text] [Related]
14. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Beghetti M; Galiè N
J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
[TBL] [Abstract][Full Text] [Related]
15. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
[No Abstract] [Full Text] [Related]
16. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
17. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
[TBL] [Abstract][Full Text] [Related]
18. Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
Pitsiou GG; Chavouzis N; Nakou C; Boutou AK; Argyropoulou P; Stanopoulos I
J Heart Lung Transplant; 2009 Jun; 28(6):651-3. PubMed ID: 19481029
[TBL] [Abstract][Full Text] [Related]
19. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
20. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Channick R; Preston I; Klinger JR
Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]